GSK’s disinvestment of Chiron Behring to Bharat Biotech
Posted on16 Feb 2019
Tagsacquisition in pharma, Bharat Biotech, Chiron Behring Vaccines, disinvestment in pharma business, GSK, Hoechst AG
Comments0
Bharat Biotech’s recent plans to acquire Chiron Behring Vaccine Private Limited from GlaxoSmithKline Asia, is expected to boost the company’s rabies vaccine... Read More
Recordati received exclusive rights to commercialize Juxtapid in Japan from Aegerion Pharmaceuticals
Posted on07 Feb 2019
TagsAegerion, HoFH, Juxtapid, Novelion Therapeutics, orphan drug, orphan drug designation, rare disease
Comments0
Recordati announces the signing of a license agreement with Aegerion Pharmaceuticals Inc., a subsidiary of Novelion Therapeutics Inc., for the exclusive rights... Read More
Glenmark Specialty S.A’s exclusive licensing agreement with Grandpharma (China) Co. Ltd for commercializing Ryaltris in China
Posted on07 Feb 2019
TagsGlemark outlicensing, global pharma licensing deal, licensing deal in pharma, outlicensing in pharma
Comments0
Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, announced that its Swiss subsidiary, Glenmark Specialty S.A, has entered into an exclusive... Read More
Abbott to acquire medical device company, Cephea Valve Technologies
Abbott, a global healthcare company, announced that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical... Read More
Bristol-Myers Squibb to acquire Celgene in deal worth $74 billion
Posted on07 Jan 2019
Comments0
BMS - Celgene acquisition deal
Pfizer and GlaxoSmithKline to merge consumer healthcare units
Pfizer Inc. and GlaxoSmithKline plc have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands.... Read More
Insight on Daiichi Sankyo’s ROS1/NTRK inhibitor DS-6051 licensing deal with AnHeart Therapeutics
Daiichi Sankyo and AnHeart Therapeutics announced they have entered into a worldwide exclusive license agreement for DS-6051, Daiichi Sankyo’s selective ROS1/NTRK inhibitor,... Read More
2018 Pharma Deal: Sanofi’s agreement to buy Bioverati @ $10.9 billion
Posted on18 Dec 2018
TagsBioverati, global pharma deals, global pharma licensing deal, pharma acquisition, pharma deal, Sanofi
Comments0
Sanofi and Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have entered into a definitive... Read More
2018 Pharma Deal: Novartis’ acquisition of AveXis: $8.1 billion
Posted on18 Dec 2018
TagsAveXis, global pharma deals, global pharma licensing deal, novartis, pharma acquisition, pharma deal
Comments0
Novartis has agreed to acquire the US-based Nasdaq-listed clinical stage gene therapy company for USD 218 per share or a total of... Read More
Is it always New molecule is first approved in USFDA, instead of the EU approval?
Well, it’s not always true. Lets look into the recent example of the new molecule approval. Brand Name: Motegrity Molecule: prucalopride Date... Read More